|
57 Products |
| 57 Products |
|
190 Diseases |  |
11246 News |  |
| «12...96979899100101102103104105106...109110» |
- | Trial completion date, Trial primary completion date: MIST: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy (clinicaltrials.gov) - Mar 29, 2018
P2/3, N=5, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Trial completion date: Nov 2017 --> Dec 2021 | Trial primary completion date: Nov 2017 --> Dec 2021
- | MK-2206 / Merck (MSD)
Journal: Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. (Pubmed Central) - Mar 28, 2018
Together our data illustrate the importance of the B55α-PP2A-AKT pathway in leukemogenesis. Screening for disruptions in this pathway at initial AML diagnosis may predict response to targeted therapies against AKT and PP2A.
- ||| Velsipity (etrasimod) / Pfizer
Enrollment closed, Enrollment change: OASIS: Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis (clinicaltrials.gov) - Mar 27, 2018
P2, N=156, Active, not recruiting, Sponsor: Arena Pharmaceuticals
Screening for disruptions in this pathway at initial AML diagnosis may predict response to targeted therapies against AKT and PP2A. Recruiting --> Active, not recruiting | N=240 --> 156
- | Zeposia (ozanimod) / BMS
Trial completion: Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS (clinicaltrials.gov) - Mar 27, 2018
P1, N=22, Completed, Sponsor: Celgene
Recruiting --> Active, not recruiting | N=240 --> 156 Active, not recruiting --> Completed
- Velsipity (etrasimod) / Pfizer
Enrollment change, Trial termination: Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations (clinicaltrials.gov) - Mar 27, 2018
P2a, N=1, Terminated, Sponsor: Arena Pharmaceuticals
Active, not recruiting --> Completed N=20 --> 1 | Recruiting --> Terminated; Sponsor decision to terminate the study
- mocravimod (KRP-203) / Priothera
Enrollment closed, Trial completion date, Trial primary completion date: A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (clinicaltrials.gov) - Mar 26, 2018
P1, N=23, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=20 --> 1 | Recruiting --> Terminated; Sponsor decision to terminate the study Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Aug 2018 | Trial primary completion date: Jan 2020 --> Aug 2018
- ||| OPL-0301 / Valo Health
Enrollment open: Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 26, 2018
P1, N=108, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Aug 2018 | Trial primary completion date: Jan 2020 --> Aug 2018 Not yet recruiting --> Recruiting
- |||||||||| Zeposia (ozanimod) / BMS
New P3 trial: An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Mar 15, 2018
P3, N=1200, Not yet recruiting, Sponsor: Celgene
- |||||||||| Zeposia (ozanimod) / BMS
New P3 trial: A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Mar 12, 2018
P3, N=485, Not yet recruiting, Sponsor: Celgene
- ||| OPL-0301 / Valo Health
New P1 trial: Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 11, 2018
P1, N=108, Not yet recruiting, Sponsor: Sanofi
- || fingolimod / Generic mfg.
Trial initiation date: PASSAGE: Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=3620, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Aug 2011 --> Apr 2003
- |||||||||| Zeposia (ozanimod) / BMS
New P3 trial: Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Feb 22, 2018
P3, N=600, Not yet recruiting, Sponsor: Celgene
- |||||||||| Zeposia (ozanimod) / BMS
New P3 trial: Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Feb 22, 2018
P3, N=600, Not yet recruiting, Sponsor: Celgene
- Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment change, Trial initiation date: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD (clinicaltrials.gov) - Jan 31, 2018
P2, N=1, Terminated, Sponsor: Actelion
Initiation date: Aug 2011 --> Apr 2003 N=30 --> 1 | Initiation date: Feb 2016 --> Sep 2016
- | Journal: Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. (Pubmed Central) - Jan 22, 2018
OSU-2S induced reactive oxygen species (ROS) in canine lymphoma cells and inhibition of ROS partially rescued OSU-2S-mediated cell death. These studies provide a rational basis for the use of spontaneous lymphoma in pet dogs as a preclinical large animal model for the development of OSU-2S as small molecule for treating people and dogs with lymphoma.
- || fingolimod / Generic mfg.
Biomarker, Trial primary completion date, IO biomarker: FLUENT: A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod (clinicaltrials.gov) - Jan 9, 2018
P4, N=400, Recruiting, Sponsor: Novartis Pharmaceuticals
These studies provide a rational basis for the use of spontaneous lymphoma in pet dogs as a preclinical large animal model for the development of OSU-2S as small molecule for treating people and dogs with lymphoma. Trial primary completion date: Jun 2019 --> Dec 2018
- | Veyonda (idronoxil) / Noxopharm
Enrollment closed, Combination therapy, Monotherapy: Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours (clinicaltrials.gov) - Jan 9, 2018
P2a, N=36, Active, not recruiting, Sponsor: Noxopharm Limited
Trial primary completion date: Jun 2019 --> Dec 2018 Recruiting --> Active, not recruiting
- | fingolimod / Generic mfg.
Enrollment closed, Trial primary completion date: Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod (clinicaltrials.gov) - Dec 22, 2017
P=N/A, N=40, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Jun 2018
- || Zeposia (ozanimod) / BMS
Biomarker, Trial primary completion date: Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Dec 21, 2017
P2, N=69, Active, not recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Jun 2018 Trial primary completion date: Jan 2018 --> Oct 2019
- ||| BMS-986166 / BMS
Trial completion: A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects (clinicaltrials.gov) - Nov 24, 2017
P1, N=66, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2018 --> Oct 2019 Active, not recruiting --> Completed
- | Velsipity (etrasimod) / Pfizer
Enrollment open, Trial initiation date: Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis (clinicaltrials.gov) - Nov 20, 2017
P2, N=20, Recruiting, Sponsor: Arena Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Nov 2017
- | New P4 trial: PRAG-MS: Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis (clinicaltrials.gov) - Nov 17, 2017
P4, N=1360, Recruiting, Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- ||||| Mayzent (siponimod) / Novartis
New P2 trial: Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). (clinicaltrials.gov) - Nov 9, 2017
P2, N=100, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Mayzent (siponimod) / Novartis
Trial completion, Trial primary completion date: Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 7, 2017
P3, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Nov 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Jul 2017
- Veyonda (idronoxil) / Noxopharm
Enrollment open, Combination therapy: Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer (clinicaltrials.gov) - Nov 7, 2017
P1b, N=24, Recruiting, Sponsor: Noxopharm Limited
Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Jul 2017 Not yet recruiting --> Recruiting
- || BMS-986166 / BMS
Enrollment closed: A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects (clinicaltrials.gov) - Nov 6, 2017
P1, N=66, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | glatiramer acetate / Generic mfg., fingolimod / Generic mfg.
Trial primary completion date, HEOR, Patient reported outcomes: Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=157, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Sep 2018
- | Journal: FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. (Pubmed Central) - Oct 22, 2017
Trial primary completion date: Sep 2017 --> Sep 2018 Our preclinical data indicate that FTY720 is a potentially promising therapeutic agent for MM treatment.
- | zectivimod (LC51-0255) / LG Chem
Enrollment open: A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255 (clinicaltrials.gov) - Oct 18, 2017
P1, N=110, Recruiting, Sponsor: LG Chem
Our preclinical data indicate that FTY720 is a potentially promising therapeutic agent for MM treatment. Active, not recruiting --> Recruiting
- | Veyonda (idronoxil) / Noxopharm
New P1 trial, Combination therapy: Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer (clinicaltrials.gov) - Oct 11, 2017
P1b, N=24, Not yet recruiting, Sponsor: Noxopharm Limited
- | Trial primary completion date: Fingolimod in Schizophrenia Patients (clinicaltrials.gov) - Oct 11, 2017
P2, N=40, Active, not recruiting, Sponsor: Indiana University
Active, not recruiting --> Recruiting Trial primary completion date: Aug 2017 --> Dec 2017
- |||| fingolimod / Generic mfg.
Biomarker, Enrollment open, IO biomarker: FLUENT: A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod (clinicaltrials.gov) - Oct 10, 2017
P4, N=400, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- || fingolimod / Generic mfg.
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (clinicaltrials.gov) - Oct 4, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: McGill University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Phase classification: P4 --> PN/A | N=400 --> 100 | Trial primary completion date: Nov 2019 --> Nov 2017
- Enrollment change, Trial termination, Trial primary completion date: Effect of Fingolimod on Neurodegeneration (clinicaltrials.gov) - Sep 28, 2017
P4, N=4, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Phase classification: P4 --> PN/A | N=400 --> 100 | Trial primary completion date: Nov 2019 --> Nov 2017 N=120 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Jan 2017; The trial was terminated due to low enrollment.
- || fingolimod / Generic mfg.
Biomarker, Trial primary completion date, IO biomarker: FLUENT: A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod (clinicaltrials.gov) - Sep 20, 2017
P4, N=400, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
N=120 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Jan 2017; The trial was terminated due to low enrollment. Trial primary completion date: Dec 2018 --> Jun 2019
- ||||| Mayzent (siponimod) / Novartis
Enrollment closed: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (clinicaltrials.gov) - Sep 18, 2017
P3, N=1652, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2018 --> Jun 2019 Recruiting --> Active, not recruiting
- | Trial completion, Trial primary completion date: A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Sep 13, 2017
P, N=5, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017
- || Velsipity (etrasimod) / Pfizer
Trial primary completion date: Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Sep 8, 2017
P2, N=180, Recruiting, Sponsor: Arena Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Jul 2017 --> Aug 2018
- || Velsipity (etrasimod) / Pfizer
Trial primary completion date: OASIS: Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis (clinicaltrials.gov) - Sep 8, 2017
P2, N=240, Recruiting, Sponsor: Arena Pharmaceuticals
Trial primary completion date: Jul 2017 --> Aug 2018 Trial primary completion date: Nov 2016 --> Dec 2017
- |||| Ponvory (ponesimod) / J&J
Trial primary completion date, Head-to-Head: POINT: Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera (clinicaltrials.gov) - Sep 6, 2017
P3, N=600, Recruiting, Sponsor: Actelion
Trial primary completion date: Nov 2016 --> Dec 2017 Trial primary completion date: Oct 2020 --> Mar 2020
- | amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion: Extension Study of MT-1303 in Subjects With Crohn's Disease (clinicaltrials.gov) - Sep 5, 2017
P2, N=46, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Trial primary completion date: Oct 2020 --> Mar 2020 Active, not recruiting --> Completed
- | Veyonda (idronoxil) / Noxopharm
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 1, 2017
P1, N=12, Recruiting, Sponsor: Royal North Shore Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Sep 2018
- ||| BMS-986166 / BMS
Trial completion, Enrollment change: A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers (clinicaltrials.gov) - Aug 31, 2017
P1, N=213, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Sep 2018 Recruiting --> Completed | N=32 --> 213
- ||||| fingolimod / Generic mfg.
Enrollment closed: PARADIGMS: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 24, 2017
P3, N=208, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=32 --> 213 Recruiting --> Active, not recruiting
- ||||| fingolimod / Generic mfg.
Biomarker, New P4 trial, IO biomarker: FLUENT: A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod (clinicaltrials.gov) - Aug 21, 2017
P4, N=400, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Trial completion: Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant (clinicaltrials.gov) - Aug 21, 2017
P3, N=696, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- |||| Ponvory (ponesimod) / J&J
Trial primary completion date, Head-to-Head: POINT: Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera (clinicaltrials.gov) - Aug 11, 2017
P3, N=600, Recruiting, Sponsor: Actelion
No longer recruiting --> Completed Trial primary completion date: May 2020 --> Oct 2020
- fingolimod / Generic mfg.
New trial: Gilenya's Impact on Cognitive Function and Thalamic Volumes (clinicaltrials.gov) - Aug 8, 2017
P=N/A, N=20, Recruiting, Sponsor: The Cleveland Clinic
- || fingolimod / Generic mfg.
Trial primary completion date: The Gilenya Pregnancy Registry (clinicaltrials.gov) - Aug 1, 2017
P=N/A, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2020 --> Oct 2020 Trial primary completion date: Aug 2017 --> Sep 2023
- |||||||||| Ponvory (ponesimod) / Juvise Pharma, Vanda
New P3 trial: OPTIMUM-LT: Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jul 26, 2017
P3, N=800, Enrolling by invitation, Sponsor: Actelion